Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early intravenous amino acid supplementation in critically ill adults with normal kidney function
ChiCTR2100053359Phase 3Completed
- Sponsor
- Jinling Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of compound amino acid injection (18AA-VII) in critical illness (2 arms), sponsored by Jinling Hospital. Primary endpoint: All-cause mortality at day 90 after randomization. Started Dec 2021; status: completed.
02
Drugs
compound amino acid injection (18AA-VII)
03
Conditions
critical illness
Beyond the preview
Go deeper on ChiCTR2100053359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053359.